DYAX CORP. Patent applications |
Patent application number | Title | Published |
20160102150 | PLASMA KALLIKREIN BINDING PROTEINS - Plasma kallikrein binding proteins and methods of using such proteins are described. | 04-14-2016 |
20160040157 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 02-11-2016 |
20160017055 | ANTI-PLASMA KALLIKREIN ANTIBODIES - Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region. | 01-21-2016 |
20150368359 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISORDERS - The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity. | 12-24-2015 |
20150362493 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS - The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen. | 12-17-2015 |
20150362492 | EVALUATION, ASSAYS AND TREATMENT OF PKAL-MEDIATED DISORDERS - The invention provides assay methods of detecting plasma protease CI inhibitor (C1-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. | 12-17-2015 |
20150274841 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC MACULAR EDEMA - Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema. | 10-01-2015 |
20150218218 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (CMET) AND USES THEREOF - A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed. | 08-06-2015 |
20150158932 | NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES - Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens. | 06-11-2015 |
20150087533 | LIGAND SCREENING AND DISCOVERY - Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal binding site disposed between the first and second coding regions for translation of the second polypeptide in a first expression system, wherein the first and second coding regions are in the same translational orientation; (ii) modifying each nucleic acid cassette of the plurality in a single reaction mixture so that it is functional in a second expression system, wherein the first and second region remain physically attached during the modifying; (iii) introducing each modified nucleic acid cassette into a mammalian cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in the transfected cells. | 03-26-2015 |
20150023978 | ANTI MIF ANTIBODIES - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions. | 01-22-2015 |
20140335082 | COMBINATION THERAPY COMPRISING AN MMP-14 BINDING PROTEIN - Proteins that bind to matrix metalloproteinase 14, combination therapies with such proteins and methods of using such proteins are described. | 11-13-2014 |
20140335023 | PLASMA KALLIKREIN BINDING PROTEINS - Plasma kallikrein binding proteins and methods of using such proteins are described. | 11-13-2014 |
20140308206 | FC RECEPTOR BINDING PROTEINS - The disclosure relates to antibodies that bind FcRn and methods of using these antibodies. | 10-16-2014 |
20140302048 | PLASMA KALLIKREIN BINDING PROTEINS - Plasma kallikrein binding proteins and methods of using such proteins are described. | 10-09-2014 |
20140288001 | KALLIKREIN INHIBITORS AND ANTI-THROMBOLYTIC AGENTS AND USES THEREOF - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 09-25-2014 |
20140286864 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 09-25-2014 |
20140248287 | FC RECEPTOR BINDING PROTEINS - This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders. | 09-04-2014 |
20140221611 | BINDING MOLECULES FOR HUMAN FACTOR VIII AND FACTOR VIII-LIKE PROTEINS - It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure. | 08-07-2014 |
20140205545 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - The invention provides compositions and methods for therapeutic and diagnostic applications. | 07-24-2014 |
20140200165 | NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE - The present invention provides Fab libraries and methods for using the Fab libraries to obtain antibodies against a target. The Fab library of the invention contains at least 10 | 07-17-2014 |
20140193413 | ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES - The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13. | 07-10-2014 |
20140178410 | ANTIBODIES AGAINST PHOSPHORYLCHOLINE - The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22; and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24; a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25; a CDR6 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26. | 06-26-2014 |
20140135226 | DISPLAY LIBRARY PROCESS - Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed. | 05-15-2014 |
20140107041 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 04-17-2014 |
20140018261 | FOCUSED LIBRARIES OF GENETIC PACKAGES - Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies. | 01-16-2014 |
20130331289 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 12-12-2013 |
20130274112 | LIGAND SCREENING AND DISCOVERY - Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal binding site disposed between the first and second coding regions for translation of the second polypeptide in a first expression system, wherein the first and second coding regions are in the same translational orientation; (ii) modifying each nucleic acid cassette of the plurality in a single reaction mixture so that it is functional in a second expression system, wherein the first and second region remain physically attached during the modifying; (iii) introducing each modified nucleic acid cassette into a mammalian cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in the transfected cells. | 10-17-2013 |
20130244890 | EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER - Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens. | 09-19-2013 |
20130189944 | TRACKING AND REPORTING INFORMATION CHARACTERIZING ATTACKS CAUSED BY A DISEASE - Methods and apparatus for tracking and monitoring information related to an attack caused by a disease. A portable electronic device such as a smartphone or portable computer is used to collect personal information about one or more attack episodes. The personal information is associated with temporal information for the attack and the personal information and temporal information is stored in at least one storage device associated with the portable electronic device. The stored personal and temporal information may be used to generate one or more reports displaying trends for one or more report metrics. Emergency information related to the disease and stored on the portable electronic device may be output from the portable electronic device in an emergency situation. | 07-25-2013 |
20130178396 | FOCUSED LIBRARIES OF GENETIC PACKAGES - Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies. | 07-11-2013 |
20130078262 | FC RECEPTOR BINDING PROTEINS - This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders. | 03-28-2013 |
20130045218 | FC RECEPTOR BINDING PROTEINS - This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders. | 02-21-2013 |
20130040861 | NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES - Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods are disclose. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens are also disclosed. | 02-14-2013 |
20130012438 | KALLIKREIN INHIBITORS AND ANTI-THROMBOLYTIC AGENTS AND USES THEREOF - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 01-10-2013 |
20120328517 | KALLIKREIN-BINDING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES THEREOF - This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides. | 12-27-2012 |
20120322744 | POLY-PEGYLATED PROTEASE INHIBITORS - Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods. | 12-20-2012 |
20120302463 | FOCUSED LIBRARIES OF GENETIC PACKAGES - Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies. | 11-29-2012 |
20120244163 | BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF - Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways. | 09-27-2012 |
20120201756 | PLASMA KALLIKREIN BINDING PROTEINS - Plasma kallikrein binding proteins and methods of using such proteins are described. | 08-09-2012 |
20120141473 | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS - Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis. | 06-07-2012 |
20120107231 | METALLOPROTEINASE BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described. | 05-03-2012 |
20120045819 | BINDING MOLECULES FOR HUMAN FACTOR VIII AND FACTOR VIII-LIKE PROTEINS - It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure. | 02-23-2012 |
20120028840 | FOCUSED LIBRARIES OF GENETIC PACKAGES - Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies. | 02-02-2012 |
20120027774 | METALLOPROTEINASE 9 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described. | 02-02-2012 |
20120027686 | HK1-BINDING PROTEINS - The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides. | 02-02-2012 |
20120015881 | KALLIKREIN-INHIBITOR THERAPIES - Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient. | 01-19-2012 |
20110311446 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (CMET) AND USES THEREOF - A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed. | 12-22-2011 |
20110300157 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and to matrix metalloproteinase 2 and methods of using such proteins are described. | 12-08-2011 |
20110287971 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 11-24-2011 |
20110281761 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 11-17-2011 |
20110281360 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 11-17-2011 |
20110262446 | USE OF IGF-II/IGF-IIE BINDING PROTEINS FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY FIBROSIS - Methods of using proteins that bind to IGF-II and/or IGF-IIE for the treatment or prevention of systemic sclerosis-associated pulmonary fibrosis are described. | 10-27-2011 |
20110262396 | COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS - Provided are methods and compositions for using protease binding proteins in combination with other therapeutic agents to treat inflammatory disorders such as rheumatoid arthritis, psoriasis, multiple sclerosis, systemic sclerosis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease (e.g., Crohn's and ulcerative colitis). The use of the protease binding protein allows a lower dose of the other therapeutic agents to be used in the methods and compositions, such that side effects of the other therapeutic agents are reduced or removed. | 10-27-2011 |
20110200611 | PLASMA KALLIKREIN BINDING PROTEINS - Plasma kallikrein binding proteins and methods of using such proteins are described. | 08-18-2011 |
20110190159 | MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets. | 08-04-2011 |
20110172140 | Poly-Pegylated Protease Inhibitors - Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods. | 07-14-2011 |
20110172125 | LIBRARIES OF GENETIC PACKAGES COMPRISING NOVEL HC CDR1, CDR2, AND CDR3 AND NOVEL LC CDR1, CDR2, AND CDR3 DESIGNS - Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library. | 07-14-2011 |
20110152193 | INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS - This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins. | 06-23-2011 |
20110136746 | Kallikrein-Binding "Kunitz Domain" Proteins and Analogues Thereof - This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides. | 06-09-2011 |
20110135573 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and to matrix metalloproteinase 2 and methods of using such proteins are described. | 06-09-2011 |
20110086801 | PREVENTION AND REDUCTION OF BLOOD LOSS - Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass. | 04-14-2011 |
20110082054 | LIBRARIES OF GENETIC PACKAGES COMPRISING NOVEL HC CDR3 DESIGNS - Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long. Libraries encoding antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library. | 04-07-2011 |
20110059105 | TIE COMPLEX BINDING PROTEINS - Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity. | 03-10-2011 |
20110008762 | Methods for Preserving Organs and Tissues - The invention relates to a method for preserving an organ or tissue comprising contacting the organ or tissue with an effective amount of a kallikrein inhibitor and solutions useful for such a method. Also provided is a method for reducing reperfusion injury of an organ during surgery and/or following removal of the organ from a subject comprising placing the organ in an organ storage and preservative solution, wherein the solution comprises a kallikrein inhibitor. | 01-13-2011 |
20100292440 | Binding Molecules for Human Factor VIII and Factor VIII-Like Proteins - It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure. | 11-18-2010 |
20100292103 | FOCUSED LIBRARIES OF GENETIC PACKAGES - Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies. | 11-18-2010 |
20100291001 | METALLOPROTEINASE-BINDING PROTEINS - Disclosed are antibodies that interact with a matrix metalloproteases such as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies can be used, e.g., to treat or prevent metastatic disorders, hyperproliferative disorders, disorders which are characterized by excessive extracellular matrix degradation, and inflammatory disorders. | 11-18-2010 |
20100273721 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISORDERS - The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity. | 10-28-2010 |
20100266584 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF - The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3. | 10-21-2010 |
20100266490 | Metalloproteinase Binding Proteins - Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described. | 10-21-2010 |
20100261875 | Peptides that specifically bind HGF receptor (CMET) and uses thereof - A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed. | 10-14-2010 |
20100260768 | ANTI MIF ANTIBODIES - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions. | 10-14-2010 |
20100260672 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (CMET) AND USES THEREOF - A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed. | 10-14-2010 |
20100196361 | Method of inhibition of vascular development using an antibody - Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders. | 08-05-2010 |
20100183625 | Treatment of Mucositis with Kallikrein Inhibitors - Methods, kits and compositions are disclosed that include an isolated kallikrein inhibitor for the treatment of mucositis. | 07-22-2010 |
20100056761 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. | 03-04-2010 |
20090324614 | FC RECEPTOR BINDING PROTEINS - This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders. | 12-31-2009 |
20090311245 | METALLOPROTEINASE 9 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described. | 12-17-2009 |
20090311183 | METALLOPROTEINASE 12 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 12 and methods of using such proteins are described. | 12-17-2009 |
20090297449 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and to matrix metalloproteinase 2 and methods of using such proteins are described. | 12-03-2009 |
20090275124 | Methods and Compositions Comprising Anti-Idiotypic Antibodies to Anti-MMP-14 Antibodies - Provided are anti-idiotypic antibodies specific for a CDR of an anti-MMP-14 antibody for use as reagents in novel assays for anti-MMP-14 antibodies, pharmaceutical compositions and vaccines. | 11-05-2009 |
20090247453 | Kallikrein Inhibitors and Anti-thrombolytic Agents and Uses Thereof - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 10-01-2009 |
20090234101 | DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS - In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein. | 09-17-2009 |
20090234009 | Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 09-17-2009 |
20090221480 | Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 09-03-2009 |
20090215119 | METHODS FOR PRODUCING SPECIFIC BINDING PAIRS - Provided are improved methods for providing specific binding pairs (SBPs). The methods enable production of libraries of SBP members using both a large population of one member of the SBPs and a smaller, preselected population of the other member of the SBPs having affinity for a preselected target. | 08-27-2009 |
20090203060 | EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER - Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens. | 08-13-2009 |
20090186031 | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS - Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis. | 07-23-2009 |
20090162835 | Novel methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries - Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens. | 06-25-2009 |
20090036366 | INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS - This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins. | 02-05-2009 |
20090036365 | INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS - This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins. | 02-05-2009 |
20080274969 | Albumin-Fused Kunitz Domain Peptides - The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules and vectors encoding the albumin fusion proteins of the invention, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer. | 11-06-2008 |
20080254021 | TIE1-BINDING LIGANDS - Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that inhibit endothelial cell activity. | 10-16-2008 |
20080221031 | Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 09-11-2008 |
20080213253 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER - Disclosed are new methods for treatment of angiogenesis-related disorders. Angiogenesis-related disorders are treated by administration of a Tie1 ectodomain-binding agent and a vascular disrupting agent. | 09-04-2008 |
20080213251 | HK1-BINDING PROTEINS - The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides. | 09-04-2008 |